Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Cerus Corporation Stock Popped Today

By Cory Renauer - Jan 24, 2018 at 12:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Positive pivotal trial results bode well for the company's new blood transfusion product.

What happened

Cerus Corporation (CERS -1.26%) stock shot up 25.4% in early-morning trading after the company announced an important clinical trial success. The stock has settled to a gain of 21% as of 11:33 a.m. EST on Wednesday.

So what 

Sales of Intercept Blood System products designed for platelets and plasma have slowly risen since earning approvals in 2014, but Cerus Corporation's operating expenses have accelerated much faster. During the 12 months ended last September, the company's operations lost $62 million. The red blood cell component (RBC) of the company's transfusion franchise could help close the gap, and today it took a step in the right direction. 

Upward sloping chart and dollar signs.

Image source: Getty Images.

Cerus reported results from a trial that involved 86 thalassemia patients receiving transfusions with both conventional RBCs and Intercept-treated RBCs. The study met its main efficacy goal, showing treated RBCs reduced average hemoglobin consumption without setting off any safety alarms.

Thalassemia patients generally require frequent transfusions that lead to many complications. If Cerus can convince the FDA and the medical community that Intercept-treated RBCs can reduce the overall burden, a potential drug approval would be good news for the company and for thalassemia patients.

Now what

Today's results are an important step, but Cerus isn't out of the woods yet. The company's operations lost around $62 million over the past year and finished September of 2017 with just enough cash to see it through the next 12 months.

Today's results come from just one of three phase 3 trials the company will run to support a planned submission to the FDA. Last November, the Agency granted Cerus permission to begin a much larger, 600-patient study to assess the ability of Intercept-treated RBCs to reduce kidney injury among patients undergoing heart surgeries.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cerus Corporation Stock Quote
Cerus Corporation
CERS
$5.48 (-1.26%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.